Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications

Blood

Volumn 116, Issue 12, 2010, Pages 2019-2025

  Bianchi, Giada ^a   Kyle, Robert A ^a   Colby, Colin L ^a   Larson, Dirk R ^a   Kumar, Shaji ^a   Katzmann, Jerry A ^a   Dispenzieri, Angela ^a   Therneau, Terry M ^a   Cerhan, James R ^a   Melton III, L Joseph ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PANCYTOPENIA; PATHOLOGIC FRACTURE; PATIENT MONITORING; PLASMA CELL; PRIORITY JOURNAL; COMPLICATION; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; OBSERVATION; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; EARLY DIAGNOSIS; HUMANS; MIDDLE AGED; MINNESOTA; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; OBSERVATION; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 77957191216     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-277566     Document Type: Article

References (28)

1. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
2. Axelsson U, Bachmann R, Hallen J. Frequency of pathologic proteins (M-components) on 6995 sera from an adult population. Acta Med Scand. 1966;179(2):235-247.
3. Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol. 1982;35(1):63-68. (Pubitemid 12180852)
4. Fine JM, Lambin P, Leroux P. Frequency of monoclonal gammapathy ('M components') in 13,400 sera from blood donors. Vox Sang. 1972;23(4):336-343.
5. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3):904-906. (Pubitemid 43156286)
6. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82(12):1468-1473. (Pubitemid 350211693)
7. Bowden M, Crawford J, Cohen HJ, Noyama O. A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly. J Am Geriatr Soc. 1993;41(1):11-14. (Pubitemid 23018043)
8. Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc. 2007;82(12):1474-1479. (Pubitemid 350211694)
9. Munshi NC. Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc. 2007;82(12):1457-1459. (Pubitemid 350211690)
10. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134(6):573-589.
11. Malacrida V, De Francesco D, Banfi G, Porta FA, Riches PG. Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital. J Clin Pathol. 1987;40(7):793-797. (Pubitemid 17094600)
12. Rajkumar SV, Buadi F. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol. 2007;20(4):665-680. (Pubitemid 350215386)
13. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-817.
14. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009;147(1):22-42.
15. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc. 2004;79(7):859-866.
16. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol. 2007;139(5):730-743. (Pubitemid 350115735)
17. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569. (Pubitemid 34438817)
18. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20(6):1625-1634. (Pubitemid 34260544)
19. van de Poel MH, Coebergh JW, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. Br J Haematol. 1995;91(1):121-125.
20. Go RS. Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma? Br J Haematol. 2010;149(4):620-621.
21. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
22. San-Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol. 2008;26(16):2761-2766.
23. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-1127.
24. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15(8):1274-1276. (Pubitemid 32776453)
25. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114-122.
26. Mateos MV, López-Corral L, Hernández MT, et al. Multicenter, randomized, open-label, phase III trial of lenalidomide- dexamethasone (len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: rtesults of the first interim analysis [abstract]. Blood. 2009;114(22). Abstract 614.
27. Brody H. Medicine's ethical responsibility for health care reform: the top five list. N Engl J Med. 2010;362(4):283-285.
28. Luft HS. Health care reform: toward more freedom, and responsibility, for physicians. N Engl J Med. 2009;361(6):623-628.